| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
752.85(B) |
| Last
Volume: |
3,037,186 |
Avg
Vol: |
3,290,337 |
| 52
Week Range: |
$423.21 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
220,750 |
870,750 |
2,710,260 |
6,211,418 |
| Total Sell Value |
$171,350,547 |
$608,250,580 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
3 |
13 |
42 |
89 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Lilly Endowment Inc |
10% Owner |
– – • |
2021-12-30 |
4 |
S |
$279.55 |
$1,010,276 |
D/D |
(3,614) |
107,463,810 |
|
-3% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-12-27 |
4 |
S |
$279.53 |
$997,925 |
D/D |
(3,570) |
107,467,424 |
|
-5% |
|
| Johnson Kimberly H |
Director |
– • – |
2021-12-20 |
4 |
A |
$263.48 |
$9,749 |
D/D |
37 |
1,054 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-12-20 |
4 |
A |
$263.48 |
$2,108 |
D/D |
8 |
62,095 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-12-20 |
4 |
A |
$0.00 |
$0 |
D/D |
41 |
51,096 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-12-16 |
4 |
S |
$279.82 |
$49,768,773 |
D/D |
(177,616) |
107,470,994 |
|
-7% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-12-15 |
4 |
S |
$267.37 |
$55,739,338 |
D/D |
(205,000) |
107,648,610 |
|
-4% |
|
| Johnson Kimberly H |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$170,047 |
D/D |
658 |
1,014 |
|
- |
|
| Kaelin William G Jr |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
19,704 |
|
- |
|
| Eskew Michael L |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
45,080 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
68,564 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
13,440 |
|
- |
|
| Jackson Jamere |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
7,766 |
|
- |
|
| Runge Marschall S |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
15,181 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$177,025 |
D/D |
685 |
62,035 |
|
- |
|
| Greene Gabrielle E |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
677 |
|
- |
|
| Baicker Katherine |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
21,307 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$185,811 |
D/D |
719 |
50,878 |
|
- |
|
| Walker Karen |
Director |
– • – |
2021-11-15 |
4 |
A |
$258.43 |
$174,957 |
D/D |
677 |
4,950 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-11-04 |
4 |
S |
$266.29 |
$52,419,318 |
D/D |
(195,000) |
107,853,610 |
|
-6% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-10-28 |
4 |
S |
$252.55 |
$45,236,369 |
D/D |
(178,631) |
108,048,610 |
|
-5% |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2021-10-27 |
4 |
S |
$252.33 |
$5,391,997 |
D/D |
(21,369) |
108,227,241 |
|
-6% |
|
| Johnson Kimberly H |
Director |
– • – |
2021-10-18 |
4 |
A |
$238.98 |
$9,559 |
D/D |
40 |
354 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2021-10-18 |
4 |
A |
$238.98 |
$1,912 |
D/D |
8 |
61,349 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2021-10-18 |
4 |
A |
$238.98 |
$10,993 |
D/D |
46 |
50,159 |
|
- |
|
1437 Records found
|
|
Page 17 of 58 |
|
|
23.04 (3.02%) 
